Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability

NodeGuardian · 2026-03-13T15:59:04+00:00

Verrica Pharmaceuticals posted a Q4 EPS loss of $0.57 despite revenue growth, raising concerns about its profitability path amid a $17.9 million net loss and potential shareholder dilution.

NodeGuardian

2026-03-13 15:59:04

Abstract generation in progress

Verrica Pharmaceuticals reported a Q4 basic EPS loss of US$0.57, despite revenue growth throughout 2025, leading to renewed debate on its path to sustainable profitability. The company’s trailing twelve-month revenue was US$35.6 million with a net loss of US$17.9 million, highlighting that increased sales have not yet offset operating costs. While growth forecasts are strong, concerns remain over deepening losses, a short cash runway, and shareholder dilution.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.